Company intelligence / Profile preview
Synthis Therapeutics
New York City / Manhattan, New York, United Statessynthistx.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Synthis Therapeutics is developing a first-in-class antibody-drug conjugate platform that selectively delivers a proprietary TGF-beta inhibitor to disease-driving cells. Their lead program SYN101 has demonstrated in preclinical models the ability to block tumor growth and restore immune function without the systemic toxicity seen in previous TGF-beta therapies. The approach aims to improve efficacy and safety for both oncology and fibrotic indications
- Therapeutic areas
- OncologyRare Diseases
- Modalities
- Antibody-drug conjugates (ADCs)Targeted biologics (TGF-beta inhibitor payloads)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
JLABS Manhattan location residency since winning pitch competition in 2023
Beyond the preview
Go deeper on Synthis Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Synthis Therapeutics.